| abstract |
The subject of the invention is compounds corresponding to the formula (I): in which: - R1 represents a hydrogen atom or a (C1-C4)alkyl group; - R2 represents a homopiperidin-1-yl, piperidin-1-yl, pyrrolidin-1-yl or azetidin-1-yl radical, or an amino (C1-C6)alkyl group; - or R1 and R2, together with the nitrogen atom to which they are attached, constitute a piperazin-1-yl, 1,4-diazepan-1-yl, homopiperidin-1-yl, piperidin-1-yl, pyrrolidin-1-yl or azetidin-1-yl radical; - one of the two substituents R3, R6 represents a Y-A-R9 group; - Y represents an oxygen atom, or an -S(O)n-, -OSO2- or-N(R18)- group; ‑ A represents an unsubstituted (C1-C4)alkylene group; - R9 represents an -OR12, -CN, ‑CO2H, NR12R13, -CONR12R13, -NR15COR12,-CONHNH2, -CONHOH, -CONHSO2R14, ‑S(O)nR14, -SO2NR12R13, -NR18SO2R14, or-NR15SO2NR12R13 group, or an aromatic heterocycle. The present invention also relates to the methods of preparation and the therapeutic applications of the compounds of formula (I) as cannabinoid CB1 receptor antagonists. |